Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
Roche’s Alzheimer’s antibody looks likely to join the scrapheap. But the company is determined to keep plugging away at the disease.
Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.